ADMA Biologics (NASDAQ:ADMA) Shares Up 6.1% – Time to Buy?

ADMA Biologics, Inc. (NASDAQ:ADMA)’s stock price rose 6.1% during mid-day trading on Wednesday . The stock traded as high as $19.91 and last traded at $19.85. Approximately 2,397,523 shares changed hands during mid-day trading, a decline of 28% from the average daily volume of 3,320,496 shares. The stock had previously closed at $18.71.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Stock Performance

The firm’s fifty day moving average price is $16.67 and its 200-day moving average price is $17.98. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company has a market cap of $4.74 billion, a P/E ratio of 71.57 and a beta of 0.60.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ADMA. Vanguard Group Inc. raised its stake in shares of ADMA Biologics by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company’s stock worth $312,109,000 after buying an additional 80,302 shares during the last quarter. State Street Corp increased its stake in ADMA Biologics by 61.4% in the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after purchasing an additional 4,945,063 shares in the last quarter. Geode Capital Management LLC raised its holdings in ADMA Biologics by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company’s stock worth $93,187,000 after purchasing an additional 50,399 shares during the period. Dimensional Fund Advisors LP raised its stake in ADMA Biologics by 16.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company’s stock worth $80,065,000 after buying an additional 643,661 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of ADMA Biologics by 2.8% during the 4th quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company’s stock valued at $64,654,000 after purchasing an additional 102,692 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.